RxDoctor Payments Data

Freya Silverstein, MD

Nephrology · Atlantis, FLNPI 1669467460

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 69 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$313
  • AstraZeneca$273
  • Otsuka America Pharmaceutical, Inc.$177
  • Fresenius USA Marketing, Inc.$165
  • La Jolla Pharmaceutical Company$122
  • Akebia Therapeutics Inc$101
  • plus $278 from 6 others

What the payments were for

  • Food & beverage$1,40498%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 45th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$489,712
Medicare patients
745
Services billed
4,564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone126$182,879
VelphoroSucroferric Oxyhydroxide30$150,335
FarxigaDapagliflozin Propanediol125$144,410
JardianceEmpagliflozin92$126,854
OzempicSemaglutide30$48,988
MounjaroTirzepatide17$27,496
EliquisApixaban22$24,977
LokelmaSodium Zirconium Cyclosilicate13$22,753
SpsSodium Polystyrene Sulfon/Sorb30$14,664
Cinacalcet Hcl28$12,600
Sevelamer Carbonate44$6,390
VeltassaPatiromer Calcium Sorbitex16$5,361
Calcium Acetate38$4,152
Losartan Potassium304$3,397
Potassium Chloride20$3,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$39$182,879126 claims
AstraZenecaFarxiga, Lokelma$273$167,163138 claims
Fresenius USA Marketing, Inc.Velphoro$165$150,33530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 756 nephrology providers in Florida.

Other nephrology in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →